Research on discovering and developing new drugs. Covers structure-revealing tools, eye-disease mechanisms, protein screening, and once-daily oral medicines.
A groundbreaking study has identified a dual-target approach that significantly prevents the development of resistance in bacteria. This approach combines membrane disruption with an additional critical cellular pathway, offering a potential solution to mitigate the escalating threat of antimicrobial resistance.
Researchers at UTEP secured a patent for anti-malarial drug pyronaridine, which slows cancer cell growth and induces programmed cell death, sparing healthy cells.
The FDA has resolved Novo Nordisk's Wegovy and Ozempic shortages, ensuring access to critical medications for obesity and diabetes treatment. The Obesity Society urges the FDA to enforce regulations against unauthorized GLP-1 compounders, highlighting concerns over safety and efficacy.
Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.
An international research team developed a user-friendly software method called Segment Anything for Microscopy, which can precisely segment images of tissues, cells, and similar structures. The new model improved performance for cell segmentation, enabling researchers to automate tasks that previously took weeks of manual effort.
A new study found that nearly 20% of cancer patients in middle-stage drug trials receive treatment that later gets FDA approval. This has important implications for drug development and clinical trial recruitment.
A new study using OCT imaging revealed that nerve fibers in the inner ear adjust sound levels and compensate for hearing loss. In healthy mice, cochlear activity remained stable, but in mice with genetic hearing loss, cochlear function increased to enhance sensitivity.
Researchers found that cytomegalovirus infection significantly worsens necrotizing enterocolitis in mouse models, triggering inflammation and disrupting energy production. The study provides insight into the underlying mechanisms of NEC and may lead to the development of new treatments for this devastating condition.
The ESMO Targeted Anticancer Therapies Congress 2025 features state-of-the-art presentations on new targets, tumour-agnostic drug development, and the role of artificial intelligence in cancer treatment. The congress also highlights recent study results and their potential impact on precision medicine.
New research reveals aldosterone-producing adenomas harbor at least four distinct cell types, including cortisol-producing cells that contribute to unexpected health issues. The study also identifies potential role of lipid-associated macrophages in influencing hormone production and tumor growth.
Researchers developed reprogrammed vascular endothelial cells that provide strong support for islets, allowing them to survive and reverse diabetes long-term. The study showed that mice transplanted with islet cells plus R-VECs regained normal blood glucose control after 20 weeks.
The FORESIGHT consortium aims to improve drug development through advanced nuclear and optical imaging techniques, AI expertise, and infrastructure. This will enable more efficient tracking of drug behavior in the body and better development of imaging biomarkers.
Researchers have developed two therapeutic cocktails that inhibit key molecules, stopping immune cells from overreacting to allergens. The treatments reduced asthma attacks in mice by erasing the immune system's memory of asthma-causing allergens.
Researchers at UNIGE have developed a system that uses light to activate targeted molecules, enabling spatial and temporal control over the activity of a molecule in a living organism. This technology has vast potential applications in both basic research and improving existing medical treatments, such as those for skin cancer.
A study found that pro-inflammatory molecules contribute to benign prostatic hyperplasia (BPH) in aging men, especially those with metabolic syndrome. Men with BPH had higher levels of pro-inflammatory markers and lower anti-inflammatory substances, suggesting a link between inflammation and prostate conditions.
Researchers at U of T discover a ginger compound called furanodienone that selectively binds to and regulates nuclear receptor PXR, reducing inflammation in the colon. FDN has been shown to increase tight junction proteins, repairing damage to the gut lining caused by inflammation.
Three University of Arizona Health Sciences faculty members have received career development awards to support their research. Erika Austhof will study the role of weather and ecological drivers in salmonella transmission, while Kristin Huntoon will investigate a drug for treating glioblastomas. Celina Valencia will examine the link be...
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
Researchers at Mass General Brigham used a generative AI tool to screen patients for a heart failure clinical trial, significantly improving speed and efficiency compared to manual screening. The study found that the AI-assisted screening process screened 458 eligible patients compared to 284 in the manual group.
Researchers have developed a 'gut-on-chip' model that replicates intestinal inflammation and predicts response to immunotherapy in melanoma patients. The device differentiates between major intestinal populations and reproduces realistic environments.
Researchers at the University of Illinois have developed a methodology for multiple CubeSats to act as service agents for assembling or repairing space telescopes. The method minimizes fuel consumption and guarantees safe operations without collisions.
Researchers discovered a link between neuroactive steroids in pregnant women's blood and the risk of developing postpartum depression. Measuring these molecules via a blood test could enable doctors to provide treatment sooner. The study may lead to a preventive treatment using existing prescription drugs.
Researchers at Osaka University developed a new technique called single-cell suppressive profiling of regulatory T cells (scSPOT) that can pinpoint the effects of Tregs on all other immune cells. The study found that Tregs most strongly affect CD8-EM T cells, which play a key role in fighting cancer and infections.
Researchers at the Institut Pasteur have gained a better understanding of how mpox variants become resistant to tecovirimat. They found that the drug works by binding two phospholipases together, preventing viral particles from spreading. This knowledge will help develop new antiviral treatments effective across all mpox strains.
Researchers from the University of Gothenburg have made a breakthrough in understanding the role of protein tau in Alzheimer's disease. By identifying specific amino acid modifications that occur before thread-like fibrils form, scientists hope to develop complementary drugs to combat the disease.
The PhRMA Foundation has appointed Dr. John C. Reed and Dr. Donatello Crocetta to its Board of Directors, bringing expertise in innovative medicine and medical strategy. The new additions aim to foster groundbreaking research and support the next generation of scientists.
A new method allows for accurate measurement of blood-brain barrier permeability, revealing that many CNS drugs penetrate the barrier rapidly. The study found that plasma proteins play a crucial role in maintaining brain delivery of lipophilic agents.
A team from Tokyo University of Science developed a novel trivalent platform for triple click chemistry, allowing for the efficient synthesis of complex compounds. The approach utilizes simple initial materials and promotes sustainable pharmaceutical synthesis.
New cyanine-carborane salts show promise in eradicating metastatic breast cancer tumors with minimal side effects. The therapy targets specific proteins in cancer cells, allowing for precise killing of diseased cells while sparing healthy tissue.
A new study published in the Journal of Crohn's and Colitis reveals that vancomycin may be an effective treatment for people with inflammatory bowel disease (IBD) and autoimmune liver disease. The antibiotic achieved clinical remission in 80% of patients, with significant decreases in inflammatory markers and mucosal healing.
A new 3D bioprinted gastric cancer model successfully replicates the unique characteristics of individual patients' tissues, predicting drug responses and prognosis with high accuracy. This innovative platform enables rapid evaluation within two weeks, contributing to personalized cancer treatment development.
The Terasaki Institute for Biomedical Innovation has announced the recipients of its inaugural Keith Terasaki Mid-Career Innovation Award. Dr. Liangfang Zhang and Dr. Aydogan Ozcan were recognized for their innovative approaches to translating groundbreaking research into real-world impact.
A new drug developed by the Centre for Addiction and Mental Health (CAMH) has shown significant promise in reversing memory loss in a mouse model of Alzheimer's disease. The drug, GL-II-73, selectively targets GABA receptors to restore brain function and repair damaged neural connections.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.
A team of researchers has developed a novel model of the Blood-Brain Barrier, which mimics the complex structure of cerebral blood vessels. This breakthrough enables scientists to study neuroinflammation and develop new therapeutic strategies for Alzheimer's disease and other neurodegenerative disorders.
Daniel Armstrong, a renowned UTA chemist, has been honored with the prestigious 2025 Pittcon Analytical Chemistry Award for his pioneering work in analytical chemistry. His research focuses on developing new approaches to identify chiral disease biomarkers, peptide epimers, and isotopic compounds.
Researchers at Lancaster University have developed a new method to detect Alzheimer's disease by analyzing changes in brain oxygenation dynamics and neuronal function. The study found that individuals with Alzheimer's disease exhibit altered respiratory frequency, which may be an early indicator of the condition.
A UT Health San Antonio researcher and her biotechnology company partner with the school to develop a breakthrough oral cancer drug, CIDD99. The partnership aims to create effective, less toxic cancer therapies for aggressive cancer types.
A new study suggests that women at risk of postpartum depression may have characteristic levels of neuroactive steroids in their blood during pregnancy. Elevated progesterone levels and imbalances in its metabolism may be associated with an increased risk of PPD.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
A review of cell death and aging in cancer research reveals the significance of cellular senescence in promoting cancer growth. The study highlights the potential of various types of programmed cell death, such as necroptosis and pyroptosis, as therapeutic targets against senescent cells.
Southwest Research Institute's Risk Evaluation & Medical Decision Efficacy (REMEDY) tool supports agile medical decisions on countermeasures for chemical and biological threats. The REMEDY mission risk evaluations quantify risks and benefits of medical countermeasures, enabling operational planners to make informed decisions.
Researchers identified a potential new treatment for aggressive sarcoma arising in nerves, using a pre-clinical platform that combines inhibitors targeting specific mutations. The triple combination of MEKi-BETi-CDKi showed promising results in shrinking tumors and even eliminating some cases, offering hope for improved treatment options.
A study found that people with delayed REM sleep have higher levels of toxic proteins amyloid and tau, and lower levels of healthy protein BDNF, which can increase the risk of developing Alzheimer's. Practicing healthy sleep habits may help mitigate this risk.
Researchers developed AshPhos, a ligand that facilitates the formation of carbon-nitrogen bonds using inexpensive materials. The tool has potential applications in pharmaceuticals, nanomaterials, and degrading PFAS pollutants.
A West Virginia University legal scholar argues that current laws favor biologic drugs with longer exclusivity periods, affecting their pricing. The scholar suggests reducing exclusivity for biologics to bring them in line with small-molecule drugs, which could lower drug costs.
A team from Osaka Metropolitan University has developed a crystal patterning method that controls the position and orientation of photochromic crystals, known as diarylethenes. This breakthrough allows for the creation of convex structures with precise control over crystal shape and size.
Researchers developed guidelines to compare lab experiments, molecular simulations, and AI for drug delivery testing. The new framework aims to improve the accuracy of permeability testing and accelerate the development of life-saving drugs.
A retrospective cohort study of 44,000 individuals found associations between baseline fasting glucose levels, age, sex, and body mass index with the development of diabetes. The study highlights individual variation in diabetes risk according to commonly measured clinical variables, suggesting potential for targeted interventions.
A recent study found that long COVID is more prevalent in women than men, and the association was linked to factors such as age, pregnancy, and menopausal status. The research highlights the need for targeted drug development and improved management strategies for long COVID.
PolyU's 16 projects funded by HMRF focus on healthcare innovation, covering areas like nursing care, health tech, and biomedical engineering. The research aims to address global healthcare challenges and improve overall well-being.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
A multidisciplinary team led by the Wyss Institute aims to create novel anesthesia-inducing drugs that can safely induce an anesthesia-like state without compromising vital functions. The project leverages expertise from Harvard's MCB, MIT, and Tufts University to develop safe battlefield-ready anesthetics.
Researchers discovered that the protein PIN1 drives bladder cancer by triggering cholesterol synthesis, which fuels out-of-control cell growth. A combination of statins and a PIN1 inhibitor effectively blocks tumor growth in mice, offering a promising therapeutic approach for this deadly disease.
Researchers use SCP-Nano to analyze distribution of extremely low doses of nanocarriers throughout the mouse body, visualizing each cell that has taken them up. The platform identifies unwanted accumulation in organs like the heart and liver, paving the way for safer mRNA therapeutics.
A recent NUS Medicine study found that a molecule called DUSP6 plays a major role in helping colorectal cancer grow, with higher levels linked to poorer prognosis and decreased survival. Researchers suggest blocking DUSP6 could lead to new therapies for CRC treatment.
A new strategy enhances pharmaceutical production in Chinese hamster ovary cells by knocking out a gene circuit responsible for producing lactic acid. The approach improves growth rates and significantly increases protein yield, overcoming a decades-old challenge in biomanufacturing.
Researchers developed a predictive tool using the Florey Dementia Index to forecast onset ages of mild cognitive impairment and Alzheimer's. The validated tool may help prioritize patients for disease-modifying treatments.
A new RAND study found that the median cost of developing a new drug is $150 million, while the mean cost is $369 million. Excluding high-cost outliers, the average cost drops to $950 million. The study suggests using median costs for policy discussions about pharmaceutical research and development.
Organoids, derived from stem cells, closely mimic human tissue for biomedical research and drug testing. Standardization is crucial for generating reliable results in organoid construction, requiring approved operating procedures and informed consent from donors.